Evidence map›Paper›PMID 40501736›Full record

ArticlebioRxiv : the preprint server for biology2025

Statin-dye conjugates for selective targeting of

Hye-Ran Moon, Zhenying Cai, Bo Kyung Cho, Hyeyoun Chang, Seung Taek Hong, Jean J Zhao, Ick Chan Kwon, Thomas M Roberts, Bumsoo Han, Ju Hee Ryu

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Hye-Ran MoonSchool of Mechanical Engineering, Purdue University, West Lafayette, IN, USA.
Zhenying CaiDepartment of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Bo Kyung ChoMedicinal Materials Research Center, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Hyeyoun ChangDepartment of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Seung Taek HongMedicinal Materials Research Center, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Jean J ZhaoDepartment of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Ick Chan KwonDepartment of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Thomas M RobertsDepartment of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Bumsoo HanSchool of Mechanical Engineering, Purdue University, West Lafayette, IN, USA.
Ju Hee RyuMedicinal Materials Research Center, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.

Funding

Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI ANDREW D MESECAR · 1985 to 2026
$43.4M
Indiana Clinical and Translational Sciences InstituteUM1TR004402 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI Sharon M Moe, Sarah Elizabeth Wiehe · 2023 to 2026
$21.6M
Integrating targeted therapy and immunotherapy to break through cancerR35CA210057 · NCI · DANA-FARBER CANCER INST · PI Jean Zhao · 2016 to 2026
$10.8M
Reprogramming PDAC Stroma by Targeting Coagulation in the Tumor MicroenvironmentU01CA274304 · NCI · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI Melissa L. Fishel, Matthew J. Flick · 2022 to 2026
$4.6M
Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated ThrombosisU01HL143403 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FISHEL, MELISSA L., FLICK, MATTHEW J. · 2018 to 2022
$4.2M
Investigation of novel signaling protein in 3D and in vivo PDAC models using second generation Ref-1 inhibitorsR01CA254110 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI FISHEL, MELISSA L., HAN, BUMSOO · 2021 to 2025
$2.1M
NCATS NIH HHS UM1 TR004402NCI NIH HHS P30 CA023168NCI NIH HHS R01 CA254110NCI NIH HHS R35 CA210057NCI NIH HHS U01 CA274304NHLBI NIH HHS U01 HL143403
6 · The paper itself

Abstract

Over 90% of pancreatic ductal adenocarcinoma (PDAC) patients involve

Indexed as

KRAS mutationmacropinocytosispancreatic ductal adenocarcinomaselective targetingstatin

Identifiers

PMID40501736
PMCPMC12157465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.